4immune Therapeutics
Pamela Layton 4immune Chief Operating Officer
Michael Brehm

Michael Brehm, Ph. D. - Scientific Advisory Board


Associate Professor, Diabetes Center of Excellence, Program in Molecular Medicine, University of Chan Massachusetts Medical School 


Dr. Brehm has over 30 years of experience in biomedical research and his laboratory is focused on the study of autoimmunity and immunological responses to cancers and to transplantation with allogeneic tissues. He received his Ph.D. in 1999 from the Department of Microbiology and Immunology at the Pennsylvania State University College of Medicine. During Dr. Brehm’s post-doctoral training at the University of Massachusetts Chan Medical School (UMCMS), he investigated how sequential viral infections impact the ability of a host to generated protective immunity and how viral infections influence transplantation tolerance that is induced by co-stimulation blockade. In 2008, he joined the Diabetes Division at the UMCMS to develop cutting edge mouse models to study human biology.

 

Dr. Brehm is currently an Associate Professor with Tenure in the Program in Molecular Medicine at the UMCMS and a member of the Diabetes Center of Excellence. Dr. Brehm’s research program is focused on understanding how human effector T cells are regulated in the context of auto-immune disease, allo-immunity, tumor immunity.


His laboratory is developing “humanized” mice to more effectively study human T cell biology, and he is the Co-Director of the UMCMS Humanized Mouse Core. He is a standing member of the Hypersensitivity, Autoimmune, and Immune-mediated (HAI) Diseases Study Section for NIH and is a member of the review panel for Charles A. King Post-Doctoral fellowships. Dr. Brehm has published over 125 manuscripts and reviews and is supported by funding from the JDRF and NIH. 


Share by: